In cells proficient in homologous recombination (HR), these lesions are repaired via BRCA1/2-mediated pathways; in HR-deficient cells, including many BRCA-mutated or HRD-positive ovarian cancers, they result in cell death through synthetic lethality [14-16]. Here, BRCA1 is linked to ovarian cancer.